ReviewResearch and reports in urology2015
Novel targeted bladder drug-delivery systems: a review.
Review in Research and reports in urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Nanoparticle-based therapeutic platforms for inflammatory disorders of the urinary system: Engineering local delivery, biointerface regulation, and smart responsive therapy.Materials today. Bio · 2026Review
- A Comprehensive Review of Current Approaches in Bladder Cancer Treatment.ACS pharmacology & translational science · 2025Review
- Drug Release via Ultrasound-Activated Nanocarriers for Cancer Treatment: A Review.Pharmaceutics · 2024Review
- Advances in experimental bladder models: bridging the gap between in vitro and in vivo approaches for investigating urinary tract infections.BMC urology · 2024Review
- Lactobacillus-Polydopamine System for Targeted Drug Delivery in Overactive Bladder: Evidence from Bladder Cell Spheroids, Rat Models, and Urinary Microbiome Profiling.International journal of nanomedicine · 2024Article
- Local Drug Delivery in Bladder Cancer: Advances of Nano/Micro/Macro-Scale Drug Delivery Systems.Pharmaceutics · 2023Review
- Selective targeting of lectins and their macropinocytosis in urothelial tumours: translation from in vitro to ex vivo.Histochemistry and cell biology · 2023Article
- Infection responsive coatings to reduce biofilm formation and encrustation of urinary catheters.Journal of applied microbiology · 2023Article
- Utilizing 4D Printing to Design Smart Gastroretentive, Esophageal, and Intravesical Drug Delivery Systems.Advanced healthcare materials · 2023Review
- Insights into the Safety and Versatility of 4D Printed Intravesical Drug Delivery Systems.Pharmaceutics · 2023Article
- Nanomedicine for Combination Urologic Cancer Immunotherapy.Pharmaceutics · 2023Review
- Nano-BTA: A New Strategy for Intravesical Delivery of Botulinum Toxin A.International neurourology journal · 2022Article
- Combined Self-Assembled Hendeca-Arginine Nanocarriers for Effective Targeted Gene Delivery to Bladder Cancer.International journal of nanomedicine · 2022Article
- Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy.Frontiers in oncology · 2022Review
- Intravesical drug delivery approaches for improved therapy of urinary bladder diseases.International journal of pharmaceutics: X · 2021Review
- One-Step Microfluidic Fabrication of Multi-Responsive Liposomes for Targeted Delivery of Doxorubicin Synergism with Photothermal Effect.International journal of nanomedicine · 2021Article
- Article
- Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation.Drug delivery and translational research · 2020Review
- Article
- Experimental Cannabinoid 2 Receptor Activation by Phyto-Derived and Synthetic Cannabinoid Ligands in LPS-Induced Interstitial Cystitis in Mice.Molecules (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of pharmaceutics is the development of drugs with increased efficacy and reduced side effects. Prolonged exposure of the diseased tissue to the drug is of crucial importance. Drug-delivery systems (DDSs) have been introduced to control rate, time, and place of release. Drugs can easily reach the bladder through a catheter, while systemically administered agents may undergo extensive metabolism. Continuous urine filling and subsequent washout hinder intravesical drug delivery (IDD). Moreover, the low permeability of the urothelium, also described as the bladder permeability barrier, poses a major challenge in the development of the IDD. DDSs increase bioavailability of drugs, therefore improving therapeutic effect and patient compliance. This review focuses on novel DDSs to treat bladder conditions such as overactive bladder, interstitial cystitis, bladder cancer, and recurrent urinary tract infections. The rationale and strategies for both systemic and local delivery methods are discussed, with emphasis on new formulations of well-known drugs (oxybutynin), nanocarriers, polymeric hydrogels, intravesical devices, encapsulated DDSs, and gene therapy. We give an overview of current and future prospects of DDSs for bladder disorders, including nanotechnology and gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.